Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H12O3 |
Molecular Weight | 252.2647 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C2C(=O)C3=C(C=CC=C3)C2=O
InChI
InChIKey=XRCFXMGQEVUZFC-UHFFFAOYSA-N
InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
DescriptionSources: http://www.rxlist.com/miradon-drug.htmCurator's Comment: description was created based on several sources, including:
http://www.druglib.com/activeingredient/anisindione/ | http://en.pharmacodia.com/web/drug/1_7940.html
Sources: http://www.rxlist.com/miradon-drug.htm
Curator's Comment: description was created based on several sources, including:
http://www.druglib.com/activeingredient/anisindione/ | http://en.pharmacodia.com/web/drug/1_7940.html
Anisindione (brand name Miradon) is a synthetic anticoagulant and an indanedione derivative with action similar to these of Warfarin. It is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins. Hemorrhage and/or necrosis are among the hazards of treatment with any anticoagulant and are the main serious complications of therapy. Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrombin time response, in man significantly include: adrenocortical steroids; alcohol; antacids; antihistamines; barbiturates and others.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2012 Sources: http://www.druglib.com/activeingredient/anisindione/ |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MIRADON Approved UseFor the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Launch Date1957 |
|||
Primary | MIRADON Approved UseFor the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Launch Date1957 |
|||
Preventing | MIRADON Approved UseFor the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Launch Date1957 |
|||
Primary | MIRADON Approved UseFor the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Launch Date1957 |
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C263
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ANISINDIONE
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
854
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
C47398
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
222
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
m1931
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | Merck Index | ||
|
3205
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
17941
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | RxNorm | ||
|
SUB05520MIG
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
DTXSID3022611
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
6960
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
204-186-6
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
133809
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
DB01125
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
2197
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
S747T1ERAJ
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
CHEMBL712
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
117-37-3
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
100000086948
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY | |||
|
759629
Created by
admin on Fri Dec 15 15:14:53 GMT 2023 , Edited by admin on Fri Dec 15 15:14:53 GMT 2023
|
PRIMARY |
ACTIVE MOIETY